FDA Import Alerts for Dietary Supplements: What 'Detained Without Examination' Really Means for Your Brand

Every year, tens of thousands of dietary supplement shipments enter the US from manufacturing facilities in China, India, Germany, and dozens of other countries. Most clear customs without incident. But a growing number — from brands that may have no idea they’re at risk — hit a quiet wall at the border called a Detained Without Physical Examination (DWPE) designation.

And unlike a standard FDA hold, which requires an agent to physically inspect your shipment, DWPE is automatic. Once your firm or your ingredient supplier appears on an FDA import alert, every future shipment can be detained and refused entry without anyone opening a single box.

We’ve worked with brands scrambling to recover from DWPE status after they didn’t know they were on the list until a full container was refused at the Port of Los Angeles. That’s not a problem you want to discover mid-season, with retail commitments already on the books.

What “Detained Without Physical Examination” Actually Means

FDA import alerts are official enforcement documents that instruct U.S. Customs and Border Protection (CBP) agents — working through the joint FDA-CBP electronic screening system called OASIS — to flag shipments from named firms, product categories, or countries of origin. There’s no hearing before the designation. No appeal before the detention begins. The alert is issued, and automatic holds follow every subsequent entry.

The phrase “without physical examination” carries real operational weight. Standard FDA detention means agents review a shipment by actually inspecting it — pulling samples, checking labels, verifying lot documentation. DWPE inverts that presumption entirely. The burden shifts to the importer to prove compliance before goods are released, and that proof has to satisfy FDA reviewers who are working through a queue of hundreds of similar petitions.

Three import alerts hit supplement brands most frequently:

Import Alert 54-15 covers dietary supplements and their raw ingredients that appear adulterated or misbranded — most commonly products containing undeclared pharmaceutical drug compounds marketed as “natural” or “herbal” formulas. Weight loss, sexual enhancement, and bodybuilding products dominate this list.

Import Alert 99-33 applies to any firm — manufacturer, packer, or distributor — that has failed FDA Good Manufacturing Practice inspections. Critically, this alert follows the facility, not the product. If your contract manufacturer in China is listed, every product you source from that site is subject to automatic detention, regardless of whether the specific lot ever had a compliance failure.

Import Alert 66-40 targets food and supplement shipments with pesticide residues or drug residues exceeding FDA action levels, particularly shipments from regions where agricultural chemical use differs from US norms.

Each alert has its own listed firms, its own documentation requirements for removal, and its own evidentiary threshold. Understanding which alert applies to your situation determines how you respond — and how long recovery takes.

Why Supplement Brands End Up on Import Alert

The highest-profile category is undeclared pharmaceutical adulterants, and the enforcement pattern is consistent across years of FDA data. A weight loss product is marketed as “plant-based.” A men’s health formula claims only botanical ingredients. A pre-workout boasts being stimulant-free. FDA or a third-party laboratory tests the product and finds sildenafil, tadalafil, sibutramine, or anabolic steroid compounds that have no place in a dietary supplement.

FDA’s Tainted Products Marketed as Dietary Supplements database has identified more than 1,000 individual products containing undeclared drug compounds. That’s not a fringe enforcement problem — it’s a documented, multi-year pattern concentrated in specific product categories. Once a firm or category accumulates enough flags through CFSAN’s Adverse Event Reporting System (CAERS) or laboratory surveillance programs, the import alert designation follows.

Pesticide residues are an increasingly active trigger, particularly for botanical supplements sourced from South Asian and Southeast Asian growing regions. A single multiresidue pesticide screen at a qualified laboratory tests for more than 400 individual compounds. Brands importing turmeric, ashwagandha, holy basil, or moringa in volume need to treat pesticide screening as a standard lot-release requirement — not a box to check once a year. We regularly see elevated organophosphate and pyrethroid residues in these botanicals at levels that would trigger Import Alert 66-40 thresholds.

GMP-triggered holds under Import Alert 99-33 are arguably the most frustrating, because the compliance failure belongs to your supplier, not to your brand. If FDA inspects a contract manufacturer and finds inadequate sanitation records, unvalidated analytical methods, or missing batch documentation, every downstream importer sourcing from that facility can get caught in the resulting alert — even if they’ve never had a product failure of their own. Brands that don’t audit their supply chain or regularly verify their suppliers’ GMP status are genuinely flying blind.

How Pre-Import Testing Keeps You Off the List

The most effective defense against import alert exposure is documentation-forward testing — generating credible analytical evidence before any shipment arrives at a US port of entry.

For Import Alert 54-15 risks, FDA expects targeted analytical testing of finished products using validated methods. LC-MS/MS — liquid chromatography tandem mass spectrometry — is the standard analytical technique for pharmaceutical adulterant screening because of its specificity and sensitivity. A PDF from an overseas manufacturer’s in-house quality control lab doesn’t carry the same weight as results from an ISO 17025 accredited third-party laboratory running a validated, scope-covered method. Accreditation matters because it signals to FDA reviewers that the testing was conducted under a defined quality management system, with documented method validation, calibration records, and proficiency testing participation.

For pesticide residue risk under Import Alert 66-40, pre-shipment testing of each incoming botanical ingredient is the defensible standard of care. This means testing every production lot — not relying on a single annual analysis of one reference batch. Regulatory reviewers at FDA notice when a brand’s testing program doesn’t reflect the batch-to-batch variability inherent in natural agricultural products, and that inconsistency can itself raise questions about the adequacy of the compliance program.

For GMP-related concerns, ISO 17025 testing alone won’t override a supplier’s failed FDA inspection. But it can demonstrate that your brand has an independent verification layer operating in parallel — and that matters when FDA considers whether to extend DWPE to downstream importers who rely on a flagged facility.

The documentation package matters as much as the results themselves. A submission that satisfies FDA reviewers includes: the analytical COA with specific method reference numbers, the testing laboratory’s current accreditation certificate with scope appendix (confirming those methods are covered), chain of custody records, and a clear narrative of the sampling protocol. Missing any one of these elements creates grounds for FDA to ask for supplementary information — adding weeks to an already slow review process.

Getting Removed from DWPE Status: What the Process Actually Looks Like

If your firm or a product category you’re importing is already under DWPE, removal is achievable — but it’s not fast, and it’s not guaranteed on the first attempt.

For most Import Alert 54-15 cases, FDA’s standard benchmark is evidence from five consecutive compliant shipments before removal is considered. That phrase deserves precise interpretation. It doesn’t mean five shipments where nothing went wrong by chance. It means five shipments, each one accompanied by affirmative analytical documentation demonstrating the absence of the specific adulteration concern — screened by validated methods, from an accredited laboratory, across different manufacturing lots. The same compound class that triggered the original alert needs to be addressed in every submission.

Under the best circumstances, that process takes six to twelve months. It requires coordinated effort between the brand’s regulatory team, their testing laboratory, and often a qualified regulatory consultant who understands how OASIS interprets incoming customs entries and how FDA’s import operations center processes removal petitions. Submission quality affects timeline significantly — clean, well-organized packages with complete documentation chains move faster than partially assembled files that require back-and-forth with the agency.

Import Alert 99-33 removals require a fundamentally different approach. The supplier facility itself must demonstrate GMP compliance, either through a satisfactory FDA re-inspection or through a detailed corrective action plan reviewed and accepted at the agency level. Testing documentation from the importer can support the case, but it doesn’t substitute for the facility-level resolution. If your supplier can’t or won’t engage in the remediation process, the realistic path forward is qualifying an alternate supplier and rebuilding the supply chain from a compliant source.

The Operational Costs Most Brands Never Model in Advance

There’s a financial dimension to import alerts that rarely appears in any pre-launch risk assessment. A detained shipment isn’t free to hold while a removal petition is reviewed. FDA-supervised warehousing at a US port typically runs $0.10 to $0.50 per pound per day depending on the facility and product type. A shipment of 10,000 bottles of finished supplement product, detained for 60 days while a petition is processed, can accumulate $20,000 to $60,000 in storage and handling costs — before a single unit is sold, reconsidered, or destroyed.

If the petition fails and FDA refuses entry, the brand faces the cost of re-exporting to the country of origin (if it will accept the return shipment) or arranging FDA-witnessed destruction. Neither outcome is inexpensive. Neither recovers the inventory value.

Against that exposure, the cost of a pre-import testing program — full adulterant panel, pesticide multiresidue screen, and heavy metals analysis from a qualified ISO 17025 supplement testing lab — is a relatively modest line item.

The most practical action you can take today is to search FDA’s import alert database, publicly available at accessdata.fda.gov, for your key ingredient suppliers by firm name and country of origin. If any of your raw material suppliers appear under Import Alert 99-33, you have a supply chain risk that testing alone won’t resolve. Address it now, before a shipment is detained and the clock starts running.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Audit Readiness and Regulatory Consulting for Supplement Brands — Aurora TIC helps US manufacturers and importers prepare for FDA inspections, document quality systems, and navigate enforcement responses.
• Raw Material Testing and Supplier Qualification for Ingredient Importers — Ayah Labs provides contract testing and COA verification services for global B2B raw material sourcing programs.
• Canadian NHP Import Requirements and Health Canada Compliance — If your brand sells in Canada, Androxa covers NHP licensing, Health Canada testing standards, and cross-border compliance strategy.